Correlative Biomarker Study in Patients With Myeloproliferative Disorders

Description

Researchers will use abnormal blood and/or bone marrow cells, or materials derived from these abnormal cells, like DNA, RNA, protein or plasma, in laboratory studies. Toenail clippings will provide normal material like DNA for comparison with the abnormal material derived from the blood and/or bone marrow. The results of these studies will be correlated with subjects' disease symptoms and response to their experimental treatment. The MPD-RC researchers are interested in studying molecules from the blood and bone marrow, the exact molecules changing over time with the investigators choosing only the most promising for investigation. The investigators are attempting to better understand the causes of MPD and to develop improved methods for the diagnosis and treatment of these diseases. These syndromes carry a high risk of developing leukemia. It is important to continue to learn more about these blood cancers and to learn more about the effectiveness and potential side effects of various treatments. It is believed that further basic knowledge about these cancer cells as well as the effects of treatment will lead to the improvement of current therapies and the development of entirely new treatments for these diseases. The MPD-RC is hoping to determine if a number of laboratory tests (biomarkers) will allow for the prediction of response in future patients to the treatment they would receive.

Study Start Date

April 2007

Estimated Completion Date

June 2019

Interventions

No interventions cited

Specialties

  • Internal Medicine: Hematology/Oncology
  • Oncology: Myeloproliferative Dz
  • Physician Assistant: Hematology/Oncology

MeSH Terms

  • Myeloproliferative Disease
  • Myeloproliferative Disorders
  • Polycythemia
  • Polycythemia Vera
  • Thrombocythemia
  • Thrombocytosis

Study ID

Myeloproliferative Disorders-Research Consortium -- MPD-RC 107

Status

Unknown

Trial ID

NCT00665067

Study Type

Observational

Trial Phase

N/A

Enrollment Quota

860

Sponsor

Myeloproliferative Disorders-Research Consortium

Inclusion Criteria

  • Patients are to be registered to this study if they meet the eligibility criteria for one of the MPD-RC treatment protocols linked to this study.
  • Patients diagnosed with the following Myeloproliferative disorders including: polycythemia vera (PV), idiopathic myelofibrosis (IM), and essential thrombocythemia (ET) who are participating in treatment protocols of the MPD-RC are eligible.
  • Patients must have signed an informed consent to participate in a Myeloproliferative Disorders Research Consortium (MPD-RC) treatment study to which this protocol is a companion study. The subject must also have signed a consent to participate in this mandatory companion study.

Exclusion Criteria

    See inclusion criteria.

Gender

Both

Ages

18 Years and older

Accepts Healthy Volunteers

No

Study Locations and Contact Information (23)

Study Location Distance Name Phone Email
Icahn School of Medicine at Mount Sinai - New York, New York 46.8 miles None None None
Icahn School of Medicine at Mount Sinai - New York, New York 46.8 miles John Mascarenhas MD 212-241-3417 john.mascarenhas@mssm.edu
Weill Cornell Medical College - New York, New York 50.7 miles None None None
University of Pennsylvania - Philadelphia, Pennsylvania 134.5 miles Elizabeth Hexner MD 215-662-4137 elizabeth.hexner@uphs.upenn.edu
University of Pennsylvania - Philadelphia, Pennsylvania 134.5 miles None None None
Geisinger Cancer Center - Hazleton, Pennsylvania 143.5 miles None None None
Geisinger Cancer Center - Hazleton, Pennsylvania 143.5 miles Harsh Gandhi MD 570-459-2901 hgandhi1@geisinger.edu
University of Maryland - Baltimore, Maryland 222.5 miles None None None
Georgetown University - Washington, District of Columbia 258.2 miles None None None
Georgetown University - Washington, District of Columbia 258.2 miles None None None
Duke University Medical Center - Durham, North Carolina 474.1 miles Murat Arcasoy MD 919-668-6309 arcas001@mc.duke.edu
Duke University Medical Center - Durham, North Carolina 474.1 miles None None None
Ohio State University - Columbus, Ohio 520.3 miles None None None
Ohio State University - Columbus, Ohio 520.3 miles Rebecca Klisovic MD 614-293-4696 rebecca.klisovic@osumc.edu
Wake Forest University Baptist Medical Center - Winston-salem, North Carolina 523.1 miles None None None
Wake Forest University Baptist Medical Center - Winston-salem, North Carolina 523.1 miles Dmitry Berenzon MD 336-716-5847 dberenzo@wfubmc.edu
University of Illinois at Chicago - Chicago, Illinois 748.9 miles None None None
University of Illinois at Chicago - Chicago, Illinois 748.9 miles None None None
New York Blood Center - New York, New York 758.7 miles None None None
Emory Hospital - Atlanta, Georgia 795.6 miles None None None
University of Utah - Salt Lake City, Utah 2,001.3 miles None None None
Mayo Clinic - Scottsdale, Arizona 2,167.5 miles None None None
The Palo Alto Clinic - Palo Alto, California 2,598.6 miles None None None

ClinicalTrialsLocator.com provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from ClinicalTrials.gov. This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.